These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3034145)

  • 1. In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria.
    Huovinen P; Kotilainen P
    Antimicrob Agents Chemother; 1987 Mar; 31(3):455-7. PubMed ID: 3034145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.
    Hodinka RL; Jack-Wait K; Wannamaker N; Walden TP; Gilligan PH
    Eur J Clin Microbiol; 1987 Feb; 6(1):100-3. PubMed ID: 3032607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of LY146032 alone and in combination with other antibiotics against gram-positive bacteria.
    Debbia E; Pesce A; Schito GC
    Antimicrob Agents Chemother; 1988 Feb; 32(2):279-81. PubMed ID: 2834999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms.
    Benson CA; Beaudette F; Trenholm G
    J Antimicrob Chemother; 1987 Aug; 20(2):191-6. PubMed ID: 2822645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in-vitro activity of LY146032 and eight other antibiotics against gram-positive bacteria isolated from children.
    Kline MW; Mason EO; Kaplan SL; Lamberth LB; Johnson GS
    J Antimicrob Chemother; 1987 Aug; 20(2):203-7. PubMed ID: 2822647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocci.
    Verbist L
    Antimicrob Agents Chemother; 1987 Feb; 31(2):340-2. PubMed ID: 3032099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro susceptibility of gram-positive cocci to LY146032 teicoplanin, sodium fusidate, vancomycin, and rifampicin.
    Pohlod DJ; Saravolatz LD; Somerville MM
    J Antimicrob Chemother; 1987 Aug; 20(2):197-202. PubMed ID: 2822646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of LY146032 against gram-positive isolates from cancer patients.
    Saito H; Rolston KV; Ho DH; LeBlanc B; Bodey GP
    J Antimicrob Chemother; 1987 Oct; 20(4):497-503. PubMed ID: 2824425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteria.
    Chow AW; Cheng N
    Antimicrob Agents Chemother; 1988 May; 32(5):788-90. PubMed ID: 2840019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of LY146032 against Staphylococcus aureus, Listeria monocytogenes, Corynebacterium JK, and Bacillus spp., in comparison with various antibiotics.
    Van der Auwera P; Grenier P; Klastersky J
    J Antimicrob Chemother; 1987 Aug; 20(2):209-12. PubMed ID: 2822648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria.
    Jorgensen JH; Maher LA; Redding JS
    Eur J Clin Microbiol; 1987 Feb; 6(1):91-6. PubMed ID: 3032612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of LY146032 against gram-positive bacteria.
    Silva M; Jacobus NV; Gorbach SL
    Diagn Microbiol Infect Dis; 1988 Feb; 9(2):79-85. PubMed ID: 2838217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activity of the new cyclic lipopeptide LY146032 against Corynebacterium species.
    Spitzer PG; Eliopoulos GM; Karchmer AW; Moellering RC
    Eur J Clin Microbiol; 1987 Apr; 6(2):183-5. PubMed ID: 3036499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of LY146032 (daptomycin), a new peptolide.
    Ehlert F; Neu HC
    Eur J Clin Microbiol; 1987 Feb; 6(1):84-90. PubMed ID: 3032611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro activity of LY146032 against Staphylococcus aureus and S. epidermidis.
    Coudron PE; Johnston JL; Archer GL
    J Antimicrob Chemother; 1987 Oct; 20(4):505-11. PubMed ID: 2824426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.
    Jones RN; Barry AL
    Antimicrob Agents Chemother; 1987 Apr; 31(4):625-9. PubMed ID: 3038001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
    Loza E; Morosini MI; Pascual A; Tubau F; Alcalá J; Liñares J; Hernández-Bello JR; Baquero F; Perea E; Martín R; Jones RN; Cantón R;
    Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci.
    Machka K; Braveny I
    Eur J Clin Microbiol; 1987 Feb; 6(1):96-9. PubMed ID: 3032613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide.
    Sader HS; Streit JM; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2004 Nov; 50(3):201-4. PubMed ID: 15541606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003-2009).
    Sader HS; Farrell DJ; Jones RN
    J Chemother; 2011 Aug; 23(4):200-6. PubMed ID: 21803696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.